PMID- 21787242
OWN - NLM
STAT- MEDLINE
DCOM- 20120203
LR  - 20131121
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 12
IP  - 13
DP  - 2011 Sep
TI  - Abacavir and lamivudine for the treatment of human immunodeficiency virus.
PG  - 2129-38
LID - 10.1517/14656566.2011.602631 [doi]
AB  - INTRODUCTION: The introduction of combination antiretroviral therapy (cART) in 
      1996 dramatically changed the survival and the quality of life of people living 
      with human immunodeficiency virus (HIV). Viral replication can be controlled by 
      using a combination of more than 30 licensed drugs. Despite the fact that many 
      advances have been made in the last 20 years of experience with antiretrovirals, 
      certain needs remain to be addressed, such as the presence of chronic 
      inflammation, the long-term side effects of newly introduced drugs and 
      eradication. Abacavir (ABC) and lamivudine (3TC) are licensed in a fixed-dose 
      combination to be administered once daily with other antiretroviral agents for 
      the treatment of HIV. AREAS COVERED: This article provides an extensive review of 
      the evidence on the combination of ABC 600 mg and 3TC 300 mg. Specifically, it 
      discusses the chemistry-- including the phrarmacodynamics, resistance to 
      treatment, pharmacokinetics and metabolism--and formulations available. It also 
      looks at clinical efficacy, including safety and tolerability. EXPERT OPINION: In 
      the last few years, new data regarding human leukocyte antigen (HLA) B*5701 
      testing to prevent the hypersensitivity reaction due to ABC have been presented, 
      providing a landmark in the management of adverse events in HIV, and later a 
      previously unexpected correlation of the recent exposure to ABC with an increased 
      risk of cardiovascular disease. This review presents the current situation with 
      regard to the long-term efficacy and safety data on the ABC/3TC combination.
FAU - Rizzardini, Giuliano
AU  - Rizzardini G
AD  - Luigi Sacco Hospital, I Division of Infectious Diseases, Via G.B. Grassi, Milan, 
      Italy. zucchi.patrizia@hsacco.it
FAU - Zucchi, Patrizia
AU  - Zucchi P
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110725
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - 2T8Q726O95 (Lamivudine)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Anti-HIV Agents/adverse effects/*therapeutic use
MH  - Antiretroviral Therapy, Highly Active/adverse effects/methods
MH  - Clinical Trials, Phase III as Topic
MH  - Dideoxynucleosides/adverse effects/*therapeutic use
MH  - *HIV
MH  - HIV Infections/*drug therapy
MH  - Humans
MH  - Lamivudine/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Reverse Transcriptase Inhibitors/adverse effects/*therapeutic use
EDAT- 2011/07/27 06:00
MHDA- 2012/02/04 06:00
CRDT- 2011/07/27 06:00
PHST- 2011/07/27 06:00 [entrez]
PHST- 2011/07/27 06:00 [pubmed]
PHST- 2012/02/04 06:00 [medline]
AID - 10.1517/14656566.2011.602631 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2011 Sep;12(13):2129-38. doi: 
      10.1517/14656566.2011.602631. Epub 2011 Jul 25.